- Home
- TYGO vs CELU Comparison
TYGO vs CELU Comparison
Compare TYGO & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYGO
- CELU
- Stock Information
- Founded
- TYGO 2007
- CELU 2016
- Country
- TYGO United States
- CELU United States
- Employees
- TYGO N/A
- CELU N/A
- Industry
- TYGO Semiconductors
- CELU Biotechnology: Pharmaceutical Preparations
- Sector
- TYGO Technology
- CELU Health Care
- Exchange
- TYGO Nasdaq
- CELU Nasdaq
- Market Cap
- TYGO 53.5M
- CELU 49.9M
- IPO Year
- TYGO N/A
- CELU N/A
- Fundamental
- Price
- TYGO $0.87
- CELU $2.25
- Analyst Decision
- TYGO Buy
- CELU
- Analyst Count
- TYGO 3
- CELU 0
- Target Price
- TYGO $3.00
- CELU N/A
- AVG Volume (30 Days)
- TYGO 31.4K
- CELU 240.4K
- Earning Date
- TYGO 02-11-2025
- CELU 11-07-2024
- Dividend Yield
- TYGO N/A
- CELU N/A
- EPS Growth
- TYGO N/A
- CELU N/A
- EPS
- TYGO N/A
- CELU N/A
- Revenue
- TYGO $45,985,000.00
- CELU $48,200,000.00
- Revenue This Year
- TYGO N/A
- CELU N/A
- Revenue Next Year
- TYGO $57.24
- CELU $233.89
- P/E Ratio
- TYGO N/A
- CELU N/A
- Revenue Growth
- TYGO N/A
- CELU 225.94
- 52 Week Low
- TYGO $0.78
- CELU $1.30
- 52 Week High
- TYGO $2.19
- CELU $7.97
- Technical
- Relative Strength Index (RSI)
- TYGO 45.52
- CELU 45.08
- Support Level
- TYGO $0.86
- CELU $2.17
- Resistance Level
- TYGO $0.99
- CELU $2.43
- Average True Range (ATR)
- TYGO 0.07
- CELU 0.25
- MACD
- TYGO 0.02
- CELU -0.01
- Stochastic Oscillator
- TYGO 62.79
- CELU 47.13
About TYGO Tigo Energy Inc.
Tigo Energy Inc designs solar power conversion and storage products that provide customers with more choice and flexibility. Its mission is to deliver smart hardware and software solutions that enhance safety, increase energy yield, and lower operating costs of residential, commercial, and utility-scale solar systems.
About CELU Celularity Inc.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from bio-banking segment.